Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C2727
http://purl.obolibrary.org/obo/NCIT_C2727
|
|---|---|
| Preferred Name | EGFR Inhibitor PD-168393 |
| Definitions |
A quinazolone compound with anti-tumor activity. PD-168393 is a cell-permeable, irreversible, and selective inhibitor of ligand-dependent epidermal growth factor (EGF) receptor (EGFR). This agent binds to the catalytic domain of EGFR with a 1:1 stoichiometry and inactivates the EGFR tyrosine kinase activity through alkylation of a cystine residue (Cys-773) within the ATP-binding pocket, thereby inhibiting proliferation of EGFR-expressing tumor cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A quinazolone compound with anti-tumor activity. PD-168393 is a cell-permeable, irreversible, and selective inhibitor of ligand-dependent epidermal growth factor (EGF) receptor (EGFR). This agent binds to the catalytic domain of EGFR with a 1:1 stoichiometry and inactivates the EGFR tyrosine kinase activity through alkylation of a cystine residue (Cys-773) within the ATP-binding pocket, thereby inhibiting proliferation of EGFR-expressing tumor cells. |
|---|---|
| prefLabel | EGFR Inhibitor PD-168393
|
| label | EGFR Inhibitor PD-168393
|
| code | C2727
|
| Has_Target | |
| prefixIRI | NCIT:C2727
|
| in_subset | |
| Preferred_Name | EGFR Inhibitor PD-168393
|
| FDA_UNII_Code | 3R996Y9T0I
|
| Contributing_Source | FDA
|
| Chemical_Formula | C17H13BrN4O
|
| Maps_To | EGFR Inhibitor PD-168393
|
| CAS_Registry | 194423-15-9
|
| Legacy Concept Name | PD-168393
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C1518781
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |